JP Morgan Chase’s Verona Pharma VRNA Stock Holding History

JP Morgan Chase’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-150,000	Closed	-$6.97M	–	7760
2024 Q4	$6.97M	Buy	150,000 +40,000	+36%	+$1.5M	﹤0.01%	3046
2024 Q3	$3.16M	Buy	110,000 +31,600	+40%	+$778K	﹤0.01%	3594
2024 Q2	$1.13M	Buy	+78,400	New	+$1.14M	﹤0.01%	4188
2023 Q2	–	Sell	-3,200	Closed	-$64K	–	7368
2023 Q1	$64K	Buy	+3,200	New	+$69.1K	﹤0.01%	5619

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

JP Morgan Chase's VRNA Position: Q4 2025 in Review

JP Morgan Chase sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,414,770 shares — an estimated $151M sold.

JP Morgan Chase first reported a position in VRNA in Q4 2020 and held it in 15 quarters. The position peaked at $151M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

JP Morgan Chase reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
JP Morgan Chase sold 1,414,770 Verona Pharma shares in Q4 2025, an estimated $151M.
JP Morgan Chase first reported a position in Verona Pharma in Q4 2020 and held it in 15 quarters.
JP Morgan Chase's Verona Pharma position peaked at $151M in Q3 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.